Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Non-cash Items (2019 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Non-cash Items for 7 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items fell 34.61% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Dec 2025, down 34.61%, and an annual FY2025 reading of $6.0 million, up 21.33% over the prior year.
  • Non-cash Items was $6.0 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $9.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $53.3 million in Q4 2023 and bottomed at $6.0 million in Q4 2025.
  • Average Non-cash Items over 5 years is $25.3 million, with a median of $10.7 million recorded in 2022.
  • The sharpest move saw Non-cash Items skyrocketed 397.11% in 2023, then plummeted 82.65% in 2024.
  • Year by year, Non-cash Items stood at $47.1 million in 2021, then crashed by 77.24% to $10.7 million in 2022, then skyrocketed by 397.11% to $53.3 million in 2023, then tumbled by 82.65% to $9.2 million in 2024, then plummeted by 34.61% to $6.0 million in 2025.
  • Business Quant data shows Non-cash Items for ARCT at $6.0 million in Q4 2025, $9.2 million in Q4 2024, and $53.3 million in Q4 2023.